ADMA BIOLOGICS, INC. (NASDAQ:ADMA) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
On February 15, 2018, ADMA Biologics, Inc. (the “Company”) received a letter from Dr. Bernhard Ehmer notifying the Company that he has resigned as a member of the Company’s Board of Directors (the “Board”), effective immediately. This resignation was precipitated by certain commitments made by Biotest AG (“Biotest”) and Biotest Pharmaceuticals Corporation (“BPC”) with the Committee on Foreign Investment in the United States (“CFIUS”) in connection with a transaction unrelated to the Company. There wasno disagreementbetween Dr. Ehmer and the Company on any matter relating to the Company’s operations, policies or practices. Dr. Ehmer served as a member of the Board since June 2017 and did not hold any positions on any committee of the Board.
On February 15, 2018, the Company also received a letter from Michael Ramroth notifying the Company that he has resigned as an observer of the Board, effective immediately. This resignation was also precipitated by certain commitments made by Biotest and BPC with CFIUS in connection with a transaction unrelated to the Company. Mr. Ramroth served as a Board observer since June 2017.
to the terms of that certain Stockholders Agreement, dated as of June 6, 2017, by and between the Company and BPC, BPC holds the right to designate (i) one person as a nominee to the Board, subject to Board approval, and (ii) one person as a Board observer.
About ADMA BIOLOGICS, INC. (NASDAQ:ADMA)
ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.